华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03320 华润医药

已收盘 04-09 16:08:13

6.300

+0.120

+1.94%

最高6.300	最低6.090	成交量3,054万
今开6.200	昨收6.180	日振幅3.40%
总市值395.83亿	流通市值395.80亿	总股本62.83亿
成交额1.90亿	换手率0.49%	流通股本62.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03320","market":"HK","secType":"STK","nameCN":"华润医药","latestPrice":6.3,"timestamp":1775722093006,"preClose":6.18,"halted":0,"volume":30538896,"delay":0,"changeRate":0.01941747572815536,"floatShares":6282510461,"shares":6283000000,"eps":0.7375508214333284,"marketStatus":"已收盘","change":0.12,"latestTime":"04-09 16:08:13","open":6.2,"high":6.3,"low":6.09,"amount":189608296,"amplitude":0.033981,"askPrice":6.3,"askSize":801500,"bidPrice":6.29,"bidSize":74500,"shortable":3,"etf":0,"ttmEps":0.7375508214333284,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775784600000},"marketStatusCode":5,"adr":0,"listingDate":1477584000000,"exchange":"SEHK","adjPreClose":6.18,"dividendRate":0.034881,"openAndCloseTimeList":[[1775698200000,1775707200000],[1775710800000,1775721600000]],"volumeRatio":0.639055,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03320","defaultTab":"news","newsList":[{"id":"1195377338","title":"华润医药更新3月股份变动月报表，股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1195377338","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195377338?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:12","pubTimestamp":1775034774,"startTime":"0","endTime":"0","summary":"华润医药（03320）于2026年4月1日发布截至2026年3月31日的月度股份变动报告。公告显示，公司本月底已发行股份数为6,282,510,461股，与上月底持平，库藏股份数量为零。\n报告期内，公司未有新增发行、购回或注销股份活动。根据公告，公司股份期权计划仍在有效期内，如全部行使，最多可额外发行628,450,646股。截至报告期末，公司确认符合相关公众持股量要求。\n上述月度报告由公司秘书温詠宜签署。公司表示将继续遵守香港联交所《上市规则》及相关法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622829545","title":"华润医药(03320)附属华润医药商业完成发行18亿元公司债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2622829545","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622829545?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:17","pubTimestamp":1774613828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)发布公告，公司的非全资附属公司华润医药商业集团有限公司已根据中国证券监督管理委员会的批复(证监许可[2024]1356号)于中国发行首期2026年公司债券，该批复同意华润医药商业于中国向合资格投资者公开发行本金总额不超过人民币200亿元的公司债券。董事会欣然宣布，本金额人民币18亿元的首期2026年公司债券已发行，期限3年，票面年利率为1.70%。发行首期2026年公司债券所募集的所得款项净额将用于生产性支出，包括补充营运资金、偿还计息债务、项目投资以及符合适用法律法规的其他用途。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1570","BK1191","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622846075","title":"里昂：维持华润医药(03320)“跑赢大市”评级 目标价上调至7.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622846075","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622846075?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:17","pubTimestamp":1774599421,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，维持华润医药“跑赢大市”评级，考虑到去年业绩，里昂上调华润医药2026及2027年收入预测4.1%及4.8%，纯利预测上调22.6%及15%，目标价由5.6港元上调至7.2港元。华润医药去年业绩超预期，期内收入同比增长4.6%至2,695.74亿元人民币(下同)，纯利同比增长20.7%至40.5亿元，均高于市场预期，主要受惠于制药业务表现强劲、经营开支管控较佳及融资成本下降。全年毛利率及净利润率分别扩阔0.7及0.2个百分点，至16.5%及1.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622084363","title":"招商证券国际：升华润医药(03320)目标价至6.3港元 评级“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622084363","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622084363?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:09","pubTimestamp":1774595395,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券国际发布研报称，华润医药2025年制药业务部分实现收入510亿元人民币(下同)，同比增长10.2%。其中中药板块保持双位数增长，为年增13.0%，中药收入274亿元，中药处方药增速26.8%，远超OTC的5.6%，受益于天士力并表及心脑血管品种放量的结构性改善，这一趋势在今年有望延续。招商证券国际小幅提升对集团今明两年的盈利预测，目标价由5.9港元升至6.3港元，对应2026预测估值不足10倍，仍然具有吸引力;评级“增持”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06099","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622488148","title":"港股华润医药涨近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622488148","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622488148?lang=zh_cn&edition=full","pubTime":"2026-03-27 14:35","pubTimestamp":1774593349,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月27日，华润医药(03320.HK)涨近5%，截至发稿涨4.88%，报5.59港元，成交额2.48亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686936245.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686936245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1570","BK4588","03320","BK1191","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168400797","title":"异动解读 | 大行唱好目标价上调，华润医药盘中大涨5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168400797","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168400797?lang=zh_cn&edition=full","pubTime":"2026-03-27 14:32","pubTimestamp":1774593133,"startTime":"0","endTime":"0","summary":"华润医药今日盘中大涨5.25%，引起了市场的广泛关注。消息面上，招商证券国际发布研报，将华润医药的目标价由5.9元上调至6.3元，并维持“增持”评级。该行指出，公司2025年制药业务收入实现双位数增长，其中中药处方药增速显著，且管理层对2026财年收入与利润增长传递出积极信号，同时分红政策稳定，减值压力预期减小，并延续血制品领域的战略并购思路。研报认为，公司对应2026年的预测估值不足10倍，仍然具有吸引力。这些积极的财务前景与机构看好，被认为是推动股价在交易时段内显著走强的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622519668","title":"华润医药(03320)附属华润双鹤发行不超10亿元公司债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2622519668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622519668?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:03","pubTimestamp":1774523025,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)发布公告，公司非全资附属公司华润双鹤药业股份有限公司(华润双鹤)已于中国向合资格投资者发行首期公司债券(2026年公司债券)，本金总额不超过人民币10亿元，期限为3年，年息率为1.65%。发行首期2026年公司债券的所得款项净额将用于偿还计息债务及补充营运资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0239","BK0175","BK0028","BK0188","BK0185","BK1191","03320","600062","BK1570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622833759","title":"瑞银：下调华润医药(03320)目标价至6.9港元 去年收入符预期净利润胜预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2622833759","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622833759?lang=zh_cn&edition=full","pubTime":"2026-03-26 13:46","pubTimestamp":1774503968,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，上调华润医药(03320)今年至2028年每股盈利预测14%至15%，以反映税务开支及少数股东权益减少，但同时上调资本开支预测以反映业务扩张策略。该行对华润医药的目标价由7.5港元下调至6.9港元，维持“买入”评级，相当于预测今年市盈率9.3倍。该行指，公司去年收入同比增长4.6%至2,695.6亿元人民币(下同)，股东应占净利润同比增长20.7%至40.5亿元。管理层表示若撇除减值亏损等一次性项目，净利润同比升14%。该行指出，公司去年收入符合市场预期，利润则高于预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622884427","title":"华润医药早盘涨超6% 全年纯利同比增长20.73%至40.45亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622884427","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622884427?lang=zh_cn&edition=full","pubTime":"2026-03-26 10:19","pubTimestamp":1774491540,"startTime":"0","endTime":"0","summary":"　　华润医药早盘涨超6%，截至发稿，股价上涨6.24%，现报5.28港元，成交额1.92亿港元。　　华润医药发布年度业绩，集团收益人民币2695.74亿元，同比增长4.62%；股东应占溢利40.45亿元，同比增长20.73%；每股盈利0.64元；派末期息0.122元，按年同期增长约1.35倍。　　业务层面，制药业务收益510.39亿元，同比增长10.2%，中药、生物药、营养保健品及其他板块增速显著；医药分销业务收益2200.80亿元，同比增长3.2%；医药零售业务收益122.10亿元，同比增长20.8%，DTP业务增长较快。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-26/doc-inhshnxa6254994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1570","03320","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109373016","title":"异动解读 | 华润医药盘中大涨5.03%，全年纯利增超20%且末期息翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1109373016","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109373016?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:52","pubTimestamp":1774489958,"startTime":"0","endTime":"0","summary":"华润医药(03320)今日盘中大涨5.03%，引起了市场的广泛关注。消息面上，公司发布了强劲的年度业绩报告。集团全年收益达人民币2695.74亿元，同比增长4.62%；股东应占溢利为40.45亿元，同比大幅增长20.73%。此外，公司宣布派发末期股息每股0.122元，较去年同期增长约1.35倍，即实现翻倍，这显著增强了投资者对公司回报能力的信心。从业务层面看，公司的制药、医药分销及零售业务均实现稳健增长。其中，制药业务收益同比增长10.2%，医药零售业务收益更是同比增长20.8%，显示出各板块良好的发展势头。这份亮眼的成绩单是推动股价在交易时段内走强的主要动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106313230","title":"异动解读 | 华润医药(03320)盘中大涨5.17%，业绩亮眼及派息提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1106313230","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106313230?lang=zh_cn&edition=full","pubTime":"2026-03-25 09:32","pubTimestamp":1774402336,"startTime":"0","endTime":"0","summary":"华润医药(03320)今日盘中股价大幅上涨5.17%，引起了市场的广泛关注。消息面上，公司于盘前发布了截至2025年12月31日止年度的亮眼业绩。报告显示，集团收益达人民币2695.74亿元，同比增长4.62%；股东应占溢利为人民币40.45亿元，同比显著增长20.73%，实现了收入与利润的双增长。同时，董事会宣派末期股息每股人民币0.122元，并计划于2026年7月21日派发。分析认为，这份超出市场预期的年度业绩报告，以及慷慨的派息政策，是推动华润医药股价在交易时段内强劲上涨的主要动力。公司在行业竞争加剧的背景下仍能保持稳健增长，增强了投资者对其未来发展的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622019723","title":"华润医药(03320)发布年度业绩 股东应占溢利40.45亿元 同比增长20.73% 收入和利润实现双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622019723","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622019723?lang=zh_cn&edition=full","pubTime":"2026-03-25 06:50","pubTimestamp":1774392632,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药 发布截至2025年12月31日止年度业绩，集团收益人民币2695.74亿元，同比增长4.62%;股东应占溢利40.45亿元，同比增长20.73%;每股盈利0.64元;末期息0.122元。在医药行业竞争加剧、下行压力凸显的背景下，2025年本集团收入和利润实现双增长，“十四五”期间收入增速高于行业平均水平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润医药(03320)发布年度业绩 股东应占溢利40.45亿元 同比增长20.73% 收入和利润实现双增长","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03320","BK1570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143658054","title":"华润医药2025年收入与利润稳步提升，产业链布局持续优化","url":"https://stock-news.laohu8.com/highlight/detail?id=1143658054","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143658054?lang=zh_cn&edition=full","pubTime":"2026-03-25 06:16","pubTimestamp":1774390615,"startTime":"0","endTime":"0","summary":"华润医药于报告期内录得收益人民币2,695.743亿元，同比上年增长4.6%，主要来源于医药产业链的综合布局与稳健运营。销售成本为人民币2,250.665亿元，毛利达人民币445.078亿元，毛利率约16.5%。期内归属于该公司普通股股东的应占溢利为人民币40.455亿元，同比增幅20.7%，每股基本盈利为人民币0.64元；整体净利润为人民币96.53亿元，同比增长14.9%。报告期末，该公司宣派末期股息每股人民币0.122元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179420248","title":"华润医药将于2026年7月21日派发末期股息每股0.122元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179420248","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179420248?lang=zh_cn&edition=full","pubTime":"2026-03-25 06:12","pubTimestamp":1774390332,"startTime":"0","endTime":"0","summary":"华润医药宣布，董事会已就截至2025年12月31日止年度宣派每股人民币0.122元的末期股息，股息派发日定于2026年7月21日，待2026年5月29日股东大会批准后生效。公司预设派发货币为每股港币0.139元，按1人民币兑1.1363港元的汇率计算。\n股权登记方面，除净日为2026年6月3日，有关股份过户登记于2026年6月4日16:30前办理完毕。公司股票将于2026年6月5日至2026年6月8日暂停过户登记，并以2026年6月8日为记录日期。股东可于2026年7月2日16:30前选择收取人民币或港币，但仅可针对部分股息行使货币选择权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169028908","title":"华润医药截至2025年12月31日止年度营收2,059,088,027.17元，经调整净利润-7,757,477.26元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169028908","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169028908?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:47","pubTimestamp":1774007223,"startTime":"0","endTime":"0","summary":"本期信息\n截至2025年12月31日止年度，华润医药实现营收2,059,088,027.17元，同比增长18.69%。经调整净利润（扣除非经常性收益或亏损后）为-7,757,477.26元，而上年同期为301,566,307.78元，同比下降102.57%。经营活动所得现金流量净额为61,162,687.58元，同比减少79.60%。\n","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620017738","title":"华润医药(03320)：华润博雅生物2025年归母净利润约1.13亿元 同比减少71.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620017738","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620017738?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:44","pubTimestamp":1774007095,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)公布华润博雅生物2025年业绩，营业总收入约20.59亿元，同比增长18.69%;上市公司股东应占净利润约1.13亿元，同比减少71.61%;每股基本盈利0.22元，拟每10股派现金股息0.73元( 含税)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189098305","title":"华润医药2025财报：营收670.05亿元，经调整净利润163.81亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189098305","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189098305?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:26","pubTimestamp":1773926773,"startTime":"0","endTime":"0","summary":"本年度信息\n华润医药（03320）公布截至2025年12月31日止年度经审计财报，营收达到670.05亿元，同比增长8.83%。经调整净利润（扣除非经常性收益或亏损后）为163.81亿元，同比增长13.62%。经营活动产生的现金流量净额为228.92亿元，同比下降19.70%。\n","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125615969","title":"华润医药旗下昆药集团拟每10股派发现金红利1.80元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125615969","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125615969?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:14","pubTimestamp":1773922493,"startTime":"0","endTime":"0","summary":"华润医药集团旗下的昆药集团宣布，公司计划向股东实施现金分红方案，拟每10股派发1.80元人民币的现金股利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1570","BK0060","600422","BK0188","BK0239","BK0028","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126577896","title":"华润医药2025财年营收6,575,214,133.55元，经调整净利润107,110,148.34元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126577896","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126577896?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:12","pubTimestamp":1773922366,"startTime":"0","endTime":"0","summary":"本财年信息\n华润医药（股票代码：03320）公布截至2025年12月31日止年度业绩，营业总收入为6,575,214,133.55元，同比下降21.74%。经扣除非经常性损益后的净利润为107,110,148.34元，同比下降74.45%。经营活动所得现金流量净额为289,236,102.80元，同比下降64.21%。加权平均资产净值回报率为6.58%，较上年减少2.94个百分点。\n根据公告，董事会建议以实施权益分派股权登记日登记的总股本为基数，每10股派发现金股息1.80元（含税）。该建议将于2025年股东周年大会上提呈股东批准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144874377","title":"华润医药（03320）2025年度营收11,000,795,324.94元，净利润1,568,159,301.16元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144874377","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144874377?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:06","pubTimestamp":1773918361,"startTime":"0","endTime":"0","summary":"本年度信息\n截至2025年12月31日，华润医药实现营业总收入11,000,795,324.94元，同比下降1.88%。在扣除非经常性收益或亏损后，净利润达到1,568,159,301.16元，同比上升9.50%。经营活动所得现金流量净额为1,489,514,452.20元，同比下降18.39%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03320"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crpharm.com","stockEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.3582},{"period":"3month","weight":0.3377},{"period":"6month","weight":0.2638},{"period":"1year","weight":0.3068},{"period":"ytd","weight":0.3888}],"compareEarnings":[{"period":"1week","weight":0.0237},{"period":"1month","weight":0.0191},{"period":"3month","weight":-0.0098},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.2864},{"period":"ytd","weight":0.0102}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华润医药集团有限公司是一家主要从事医药业务的投资控股公司。该公司通过四个分部运营业务。制药业务分部研发、制造及销售一系列药品及保健品。药品分销业务分部向医院、分销商及零售药店等药品制造商、器械制造商及配药商提供分销、仓储、物流及其他药品供应链增值解决方案及相关服务。药品零售业务分部经营零售药店。其他业务营运分部从事持有物业及其他业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.01279},{"month":2,"riseRate":0.7,"avgChangeRate":0.045384},{"month":3,"riseRate":0.5,"avgChangeRate":0.003179},{"month":4,"riseRate":0.8,"avgChangeRate":0.04638},{"month":5,"riseRate":0.555556,"avgChangeRate":0.013028},{"month":6,"riseRate":0.333333,"avgChangeRate":0.004789},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.042472},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.002095},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.020729},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.02714},{"month":11,"riseRate":0.4,"avgChangeRate":0.010225},{"month":12,"riseRate":0.5,"avgChangeRate":-0.000929}],"exchange":"SEHK","name":"华润医药","nameEN":"CHINARES PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润医药(03320)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润医药,03320,华润医药股票,华润医药股票老虎,华润医药股票老虎国际,华润医药行情,华润医药股票行情,华润医药股价,华润医药股市,华润医药股票价格,华润医药股票交易,华润医药股票购买,华润医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润医药(03320)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润医药(03320)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}